Treatment of drug-susceptible and drug-resistant tuberculosis

Lange Christoph G.; Brehm Thomas Theo; Chesov Dumitru; Kherabi Yousra; Guglielmetti Lorenzo

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

168

SM ISO690:2012

LANGE, Christoph G., BREHM, Thomas Theo, CHESOV, Dumitru, KHERABI, Yousra, GUGLIELMETTI, Lorenzo. Treatment of drug-susceptible and drug-resistant tuberculosis. In: ERS Monograph, 2023, vol. 2023, pp. 117-138. ISSN 2312-508X. DOI: https://doi.org/10.1183/2312508X.10024622

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

ERS Monograph

Volumul 2023 / 2023 / ISSN 2312-508X /ISSNe 2312-5098

Treatment of drug-susceptible and drug-resistant tuberculosis

DOI:https://doi.org/10.1183/2312508X.10024622

Pag. 117-138

Lange Christoph G.¹²³⁴, Brehm Thomas Theo⁵², Chesov Dumitru¹²³⁶, Kherabi Yousra⁷⁸, Guglielmetti Lorenzo⁷⁸

¹ Research Center Borstel,
² German Center for Infection Research, Tuberculosis Unit, Borstel,
³ University of Lübeck,
⁴ Baylor College of Medicine,
⁵ University Medical Center Hamburg-Eppendorf, Hamburg,
⁶ ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
⁷ Sorbonne University,
⁸ National Reference Center for Mycobacteria and resistance of mycobacteria to anti-tuberculosis drugs (CNR-MyRMA)

Disponibil în IBN: 1 octombrie 2023

Rezumat

Recent advances have enabled the use of shorter TB treatment regimens. Key changes in the management of TB are: 1-month preventive treatment with rifapentine and isoniazid; 4-month treatment for paucibacillary TB in children; 4-month treatment for PTB in adults based on rifapentine; and 6-month treatment for MDR/RR-TB with bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM). However, the history of TB drug resistance, and limited capacity worldwide for DST, are cause for caution.

Cuvinte-cheie
bedaquiline, carbapenem, clofazimine, dpre1 inhibitor, ethambutol, gyrase inhibitor, isoniazid, levofloxacin, linezolid, macozinone, mmpl3 inhibitor, moxifloxacin, pretomanid, pyrazinamide, pyrifazimine, qcrb inhibitor, quinoline derivative, rifampicin, rifapentine, tedizolid, telacebec, unclassified drug

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'>
<identifier identifierType='DOI'>10.1183/2312508X.10024622</identifier>
<creators>
<creator>
<creatorName>Lange, C.</creatorName>
<affiliation>Centrul de Cercetare din Borstel, Germania</affiliation>
</creator>
<creator>
<creatorName>Brehm, T.</creatorName>
<affiliation>Centrul Medical Universitar Hamburg-Eppendorf, Hamburg, Germania</affiliation>
</creator>
<creator>
<creatorName>Chesov, D.I.</creatorName>
<affiliation>Centrul de Cercetare din Borstel, Germania</affiliation>
</creator>
<creator>
<creatorName>Kherabi, Y.</creatorName>
<affiliation>Sorbonne Université, Franţa</affiliation>
</creator>
<creator>
<creatorName>Guglielmetti, L.</creatorName>
<affiliation>Sorbonne Université, Franţa</affiliation>
</creator>
</creators>
<titles>
<title xml:lang='en'>Treatment of drug-susceptible and drug-resistant tuberculosis</title>
</titles>
<publisher>Instrumentul Bibliometric National</publisher>
<publicationYear>2023</publicationYear>
<relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>2312-508X</relatedIdentifier>
<subjects>
<subject>bedaquiline</subject>
<subject>carbapenem</subject>
<subject>clofazimine</subject>
<subject>dpre1 inhibitor</subject>
<subject>ethambutol</subject>
<subject>gyrase inhibitor</subject>
<subject>isoniazid</subject>
<subject>levofloxacin</subject>
<subject>linezolid</subject>
<subject>macozinone</subject>
<subject>mmpl3 inhibitor</subject>
<subject>moxifloxacin</subject>
<subject>pretomanid</subject>
<subject>pyrazinamide</subject>
<subject>pyrifazimine</subject>
<subject>qcrb inhibitor</subject>
<subject>quinoline derivative</subject>
<subject>rifampicin</subject>
<subject>rifapentine</subject>
<subject>tedizolid</subject>
<subject>telacebec</subject>
<subject>unclassified drug</subject>
</subjects>
<dates>
<date dateType='Issued'>2023-09-15</date>
</dates>
<resourceType resourceTypeGeneral='Text'>Journal article</resourceType>
<descriptions>
<description xml:lang='en' descriptionType='Abstract'><p>Recent advances have enabled the use of shorter TB treatment regimens. Key changes in the management of TB are: 1-month preventive treatment with rifapentine and isoniazid; 4-month treatment for paucibacillary TB in children; 4-month treatment for PTB in adults based on rifapentine; and 6-month treatment for MDR/RR-TB with bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM). However, the history of TB drug resistance, and limited capacity worldwide for DST, are cause for caution.&nbsp;</p></description>
</descriptions>
<formats>
<format>application/pdf</format>
</formats>
</resource>